Cetuximab, a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), applied together with cisplatin (cis-diamminedichloroplatinum(II); CDDP) and 5-FU, is used in recurrent/metastatic HNSCC treatment [3]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.